Amgen's Enbrel Copay Assistance Nullified: Insurer Seizes $7,700/Month Coupon

From a biopharma perspective, copay accumulators represent a direct challenge to the patient-support infrastructure built by manufacturers. Amgen’s Enbrel, costing over $7,700 a month, relies on coupons to ensure patients can afford treatment. When insurers intercept these funds, the drugmaker’s investment in access is eroded, potentially affecting brand loyalty and long-term revenue if patients abandon therapy.

Copay accumulator programs, a controversial cost-containment tactic used by commercial health insurers, have once again drawn sharp criticism after a Florida patient was forced to drain his savings to pay for a $7,700-a-month specialty drug. Larry Gruber, a fitness coach with psoriatic arthritis, had for 16 years relied on a manufacturer coupon from Amgen that covered his out-of-pocket costs for Enbrel and counted toward his deductible and out-of-pocket maximum. But when he switched to Oscar HMO of Florida in 2026, the insurer’s accumulator program pocketed that assistance, leaving him to pay the full $10,600 maximum himself—$7,600 more than he would have owed had the coupon been credited. The case illustrates a practice that has grown dramatically over the past decade, with more insurers adopting accumulators to shift specialty drug costs away from their own ledgers and onto patients and drugmakers.

“

But when he switched to Oscar HMO of Florida in 2026, the insurer’s accumulator program pocketed that assistance, leaving him to pay the full $10,600 maximum himself—$7,600 more than he would have owed had the coupon been credited.

The mechanics are straightforward: drug manufacturers like Amgen issue copay coupon cards to help patients afford high-cost brand-name drugs. Historically, that third-party payment was applied toward a patient’s annual deductible and out-of-pocket cap, accelerating the point at which the insurer’s coverage kicked in. Under an accumulator program, however, the insurer refuses to count that manufacturer assistance toward the patient’s cost-sharing obligations. The result is that the patient must exhaust their own funds—often thousands of extra dollars—before the insurer pays a dime, while the manufacturer’s intended subsidy simply reduces the insurer’s claim.

Regulatory treatment of accumulators has seesawed with political winds. In 2020, the Trump administration finalized a rule permitting insurers to exclude copay assistance from out-of-pocket calculations in certain health plans. That rule was struck down by a federal judge in 2023, who found it incompatible with the Affordable Care Act’s definition of cost-sharing. The Biden administration then issued new regulations in 2024 requiring insurers to count assistance except when a brand-name drug has a generic equivalent. Insurers sued, but a federal appeals court sided with the government in 2025. Now the Trump administration is appealing that decision, leaving the legal landscape unsettled. Meanwhile, 19 states have enacted legislation forcing insurers to apply copay assistance to patient cost-sharing, and Congress has periodically considered federal action.

The financial implications are stark. For Gruber, the accumulator meant the difference between a $3,000 liability and a $10,600 bill that wiped out his home-buying savings. Across the insured population, the cumulative effect is substantial: patients on expensive biologics for conditions like rheumatoid arthritis, multiple sclerosis, or HIV often face annual out-of-pocket exposure in the five figures, contributing to high rates of medication non-adherence and forgone care. A 2022 analysis by the IQVIA Institute found that patients with deductible exposure above $2,500 were more than four times as likely to abandon their prescriptions. The indirect costs—worsened health, emergency visits, productivity losses—can far exceed the insurer’s immediate savings.

For the insurance industry, accumulators protect medical loss ratios (MLRs) by reducing the nominal amount of claims paid, which in turn can support premium pricing and profitability. Oscar Health, a technology-focused insurer, openly defends the practice as a tool to “manage rising medical and prescription costs.” But the optics are bruising, as critics portray it as insurers pocketing money expressly given to help sick people. Patient advocacy groups such as the HIV+Hepatitis Policy Institute have been relentless in pushing for bans, arguing that accumulators effectively nullify the charitable spirit of manufacturer assistance programs and undermine the ACA’s patient protections.